Company intelligence / Profile preview

Shanghai SIMR Biotechnology Co., Ltd.

Ownership: Private
Development stage: Other

Overview

SIMR has multiple programs in clinical development, with three candidates (SR-419, SR-750, SR-1375) in Phase 2 clinical trials. SR-419, their lead product for peripheral neuropathic pain, has completed Phase 1 trials in Australia and China with positive safety results and is planning international multi-center Phase 2 clinical trials.

Therapeutic areas: PsychiatryNephrologyEndocrinologyImmunologyOncologyNeurologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

6 assets

SR1375

5 more assets in the full pipeline.

Beyond the preview

Go deeper on Shanghai SIMR Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai SIMR Biotechnology Co., Ltd..